Conquer Cancer Council

Conquer Cancer Council

Mission Statement
Conquering cancer by fostering collaborative efforts between critical stakeholders.

A community of organizations working together to improve the quality of care in cancer.

About the Conquer Cancer Council (CCC)
The Conquer Cancer Council invites for-profit and non-profit organizations committed to improving cancer care in their communities to join us. We provide a forum for like-minded organizations made up of advocates, clinicians, researchers, industry stakeholders and more to work together on key issues within the domains of cancer care and learn from one another. Each member organization positively impacts cancer care by bringing unique perspectives and insights to the table. We believe that when key stakeholders communicate and collaborate, we achieve our collective goal to improve quality of care for patients at all levels. 

Goals and Expected Outcomes

We know that to achieve our vision and mission, our goals need to be plentiful and encompass the short term and long term. Our overarching Goals are: Gain perspectives on Member insights and challenges; Provide opportunities for Members to work together on key issues; Promote the highest quality of patient care; and Advance innovation that impacts quality of patient care.

Our overarching Expected Outcomes include: Increased collaborations between Members; Improved communication between all stakeholders; and Engaging in transparent discussions to improve quality of care.

Highlights from previous CCC Annual Meetings:

  • In Fall 2017, Conquer Cancer hosted the inaugural Annual Meeting around the topic of precision medicine in oncology. The meeting featured several panel discussions and expert speakers that highlighted current challenges in precision medicine both at the provider and the patient level. 
  • The second Annual Meeting discussed how the oncology community can rethink clinical research, particularly as it relates to pragmatic and adaptive trials. Expert faculty and panel discussants spoke about meaningful data collection in oncology trials, the role of pragmatic and adaptive trials in evidence generation and patient-focused drug development.

CCC Subgroups

  • The Conquer Cancer Council Advisory Group (CCCAG): The CCCAG is intended to provide Conquer Cancer with the valuable expertise, experience and perspectives of the diverse group of CCC members through feedback and recommendations on the CCC program including with respect to strategic goals and achievement of our vision. There are a limited numbers of seats to participate in the CCCAG and participants are selected based on first come, first served basis. 
  • The Oncology Measures Advisory Group (OMAG): The OMAG is intended to provide Conquer Cancer and ASCO with perspectives that we believe are a necessary component of developing measures that reflect the highest quality of care, are responsive to the needs of measure users and—most importantly—keep the patient at their core.  Some of the questions we’d like to explore with this group are: How can we overcome challenges in using measures to drive meaningful improvements in oncology patient care and outcomes? What gaps exist in currently available oncology measure sets? Are these gaps primarily in specific clinical areas or cross-cutting for multiple cancer diagnoses? In your view, how should performance measures interact with other tools used to improve clinical performance (such as clinical pathways)?
    • Please note that the OMAG will not participate in the technical development of measures or measure sets.  The OMAG will provide guidance and advice to Conquer Cancer and ASCO subject to the understanding that ASCO’s measures are developed in accordance with ASCO principles, and that ASCO has the sole discretion to determine which measures it ultimately develops, based on its current priorities and principles. 

2019 Members

On behalf of Conquer Cancer, we would like to thank and welcome the following members for joining the Conquer Cancer Council!

Abbie Agios Amgen
Array Biopharma AstraZenaca BCRF
Bristol Myers Daiichi Sankyo Eisai
Exelixis FLASCO Foundation Medicine
Gateway Genentech Genomic
GSK Halozyme Health Monitor Network
Helsinn Kite A Gilead Company Loxo
Merck NNECOS Novartis
Paxman Pfizer Pharmacyclics
UHN Princess Margaret Cancer Center Puma Biotechnology Rakuten Medical
Sandoz The Songtag Foundation Syndax
Taiho Oncology Takeda  


Joining the Conquer Cancer Council

The 2019 Conquer Cancer Council runs from June 1, 2019 - May 31, 2020. Member applications for 2019 are now closed.  2020 applications will open December 2019/January 2020.

Contact Us

Please contact with any questions or for more information.